LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lexeo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.76+0.12 (+4.55%)
Close on Oct 19, 2026
- Market cap
- $236.33M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.82 (−71.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $236.33M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.01
- Dividend yield
- –
- Free cash flow yield
- -37.53%
Fundamentals
- Net income
- -$87.30M
- EPS, diluted
- -$1.15
- Free cash flow
- -$88.70M
- Book value per share
- $2.75
- Diluted shares
- 86M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$95.12M
Net income
-$87.30M
EPS, diluted
-$1.15
Free cash flow
-$88.70M
Reported periodTrailing twelve months